The aim of this ESC Guideline is to help health professionals manage people with heart
failure (HF) according to the best available evidence. Fortunately, we now have a wealth of …

Cardiogenic shock (CS) is a complex multifactorial clinical syndrome with extremely high
mortality, develo** as a continuum, and progressing from the initial insult (underlying …

Background Evidence to support the choice of blood-pressure targets for the treatment of
comatose survivors of out-of-hospital cardiac arrest who are receiving intensive care is …

Cardiac aging is evident by a reduction in function which subsequently contributes to heart
failure. The metabolic microenvironment has been identified as a hallmark of malignancy …

Inotropes and vasopressors frequently are administered in critically ill and perioperative
patients. However, clinical practice is highly variable across clinicians and institutions. The …

Levosimendan was first approved for clinical use in 2000, when authorization was granted
by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely …

Long-term treatment of myocardial infarction is challenging despite medical advances.
Tissue engineering shows promise for MI repair, but implantation complexity and uncertain …

Excessive mitochondrial ROS production has been causally linked to the pathophysiology of
aging in the heart and other organs, and plays a deleterious role in several age-related …

Heart failure is an epidemic disease which affects about 1% to 2% of the population
worldwide. Both, the etiology and phenotype of heart failure differ largely. Following a …

Heart failure (HF) is a major cause of mortality, hospitalizations, and reduced quality of life
and a major burden for the healthcare system. The number of patients that progress to an …